LThe main aim of this project is to provide an immunophenotypic and immunometabolic characterisation of patients with Acute Leukaemia, before and after therapy, and to understand how changes in the immune system impact the response to therapy.
Specifically:
1. The association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system will be assessed, in order to identify immune-modulatory metabolic mechanisms activated by malignant cells.
2. The association between immunometabolic signatures and response to therapies will be assessed.
3. The role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells will be explored.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
PATIENT
* Diagnosis of Acute Leukaemia.
* Eligibility for a treatment scheme involving either conventional chemotherapy or innovative therapies, such as monoclonal antibodies, molecular therapies with specific targets, metabolic and immunological therapies.
* age ≥ 18 years.
* Signature of informed consent by patients at the time of diagnosis.
Healthy donors (AIL BOLOGNA ODV volunteers)
* age ≥ 18 years.
* Signature of informed consent.
Exclusion Criteria:
* no one
Primary outcome measure(s)
the association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system, in order to identify immuno-modulatory metabolic mechanisms implemented by malignant cells — Once the sample is collected, through study completion, an average of 1 year molecular and metabolic characterisation of the bone marrow infiltrate
the association between immunometabolic signatures and response to therapies — Once the sample is collected, through study completion, an average of 1 year evaluation of the immunometabolic profile pre- and post therapy and possible relapse
the role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells — Once the sample is collected, through study completion, an average of 1 year Characterisation of the vesicular component EV and by modulating various metabolic
Trial sites (1)
Facility
City
Region
Status
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna
Bologna
Recruiting
More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
